Article Details
Retrieved on: 2024-04-29 10:47:29
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
** Truist Securities ("buy", PT: $195) says concerns over Humira are overdone given long-term growth from co's portfolio and product pipeline.
Article found on: www.tradingview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here